The promise of Immuno-oncology: Implications for defining the value of cancer treatment
JournalJournal for ImmunoTherapy of Cancer
PublisherBioMed Central Ltd.
MetadataShow full item record
AbstractThe rapid development of immuno-oncology (I-O) therapies for multiple types of cancer has transformed the cancer treatment landscape and brightened the long-term outlook for many patients with advanced cancer. Responding to ongoing efforts to generate value assessments for novel therapies, multiple stakeholders have been considering the question of "What makes I-O transformative?" Evaluating the distinct features and attributes of these therapies, and better characterizing how patients experience them, will inform such assessments. This paper defines ways in which treatment with I-O is different from other therapies. It also proposes key aspects and attributes of I-O therapies that should be considered in any assessment of their value and seeks to address evidence gaps in existing value frameworks given the unique properties of patient outcomes with I-O therapy. The paper concludes with a "data needs catalogue" (DNC) predicated on the belief that multiple key, unique elements that are necessary to fully characterize the value of I-O therapies are not routinely or robustly measured in current clinical practice or reimbursement databases and are infrequently captured in existing research studies. A better characterization of the benefit of I-O treatment will allow a more thorough assessment of its benefits and provide a template for the design and prioritization of future clinical trials and a roadmap for healthcare insurers to optimize coverage for patients with cancers eligible for I-O therapy. Copyright 2019 The Author(s).
SponsorsDevelopment of this paper was supported by Pfizer Oncology and Merck KGaA.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85065867563&doi=10.1186%2fs40425-019-0594-0&partnerID=40&md5=58f5d54bb03295285442e0327611a7f9; http://hdl.handle.net/10713/10795
- Customer pyramid framework for CAR T-cell therapies in immuno-oncology.
- Authors: Malik NN, Durdy MB
- Issue date: 2016 Oct
- Advanced APMs and the emerging role of immuno-oncology agents: balancing innovation and value.
- Authors: Seiden MV, Neubauer M, Verrilli D
- Issue date: 2017 Feb
- Clinical development of immuno-oncology in China.
- Authors: Wu DW, Huang HY, Tang Y, Zhao Y, Yang ZM, Wang J, Wang SH, Yu Y, Fang Y, Fang H, Bai Y, Sun C, Fan Q, Yu AQ, Wang HL, Du CX, Chen K, Huang MD, Zhang Y, Li N, Xu BH, Sun Y, He J
- Issue date: 2020 Aug
- Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
- Authors: Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM
- Issue date: 2017 Sep 1
- The hubris and humility of cancer pharmacology in the post immuno-oncology era.
- Authors: Lazo JS
- Issue date: 2019 Dec